| Literature DB >> 17637914 |
Maritta S Jaakkola1, Jouni J K Jaakkola.
Abstract
BACKGROUND: Office exposures have been linked to symptoms of sick building syndrome, but their relation to the development of asthma has not been studied previously. These exposures have increasing importance because an increasing proportion of the workforce is working in office environments.Entities:
Mesh:
Year: 2007 PMID: 17637914 PMCID: PMC1913573 DOI: 10.1289/ehp.9875
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Characteristics of the study population, The Finnish Environment and Asthma Study, 1997–2000.
| Characteristic | Cases No. (%) | Controls No. (%) |
|---|---|---|
| Total no. of subjects | 133 | 316 |
| Sex | ||
| Male | 41 (30.8) | 163 (51.6) |
| Female | 92 (69.2) | 153 (48.4) |
| Age (years) | ||
| 21–29 | 15 (11.3) | 34 (10.8) |
| 30–39 | 34 (25.6) | 93 (29.4) |
| 40–49 | 43 (32.3) | 99 (31.3) |
| 50–59 | 37 (27.8) | 79 (25.0) |
| 60–64 | 4 (3.0) | 11 (3.5) |
| Education | ||
| No vocational schooling | 13 (9.9) | 21 (6.7) |
| Vocational course | 18 (13.6) | 20 (6.4) |
| Vocational institution | 14 (10.6) | 43 (13.7) |
| College-level education | 53 (40.2) | 134 (42.5) |
| University or corresponding | 34 (25.8) | 97 (30.8) |
| Smoking | ||
| No | 66 (50.0) | 178 (56.3) |
| Former | 30 (22.7) | 67 (21.2) |
| Current (regular or occasional) | 36 (27.3) | 71 (22.5) |
| ETS in the workplace or at home | 16 (12.0) | 37 (11.7) |
| Visible mold or mold odor in the workplace or at home | 33 (24.8) | 65 (20.6) |
ETS, environmental tobacco smoke.
Information on education was missing for 2 subjects.
Information on smoking was missing for 1 subject.
Distribution of exposures in cases (n = 133) and controls (n = 316), and crude and adjusted OR (95% CI) of asthma in relation to exposures to paper dust, CCP, and FPP, The Finnish Environment and Asthma Study, 1997–2000.
| Exposure | Cases No. (%) | Controls No. (%) | Crude OR (95% CI) | Adjusted |
|---|---|---|---|---|
| Paper dust | ||||
| No exposure (reference) | 47 (35.3) | 178 (56.3) | 1.00 | 1.00 |
| Any exposure | 86 (64.7) | 138 (43.7) | 2.36 (1.55–3.59) | 1.97 (1.25–3.10) |
| Per 10 hr/week | 1.24 (1.11–1.41) | 1.20 (1.06–1.37) | ||
| 1 to < 30 hr/week | 28 (21.1) | 58 (18.4) | 1.83 (1.05–3.18) | 1.47 (0.81–2.67) |
| 30–60 hr/week | 58 (43.6) | 80 (25.3) | 2.75 (1.72–4.38) | 2.34 (1.41–3.89) |
| CCP | ||||
| No exposure (reference) | 90 (67.7) | 250 (79.1) | 1.00 | 1.00 |
| Any exposure | 43 (32.3) | 66 (20.9) | 1.81 (1.15–2.85) | 1.66 (1.03–2.66) |
| Per 10 hr/week | 1.11 (0.95–1.30) | 1.08 (0.92–1.27) | ||
| 1 to < 15 hr/week | 23 (17.3) | 33 (10.4) | 1.94 (1.08–3.47) | 1.89 (1.02–3.49) |
| 15–60 hr/week | 20 (15.0) | 33 (10.4) | 1.68 (0.92–3.08) | 1.45 (0.77–2.72) |
| FPP | ||||
| No exposure (reference) | 82 (61.6) | 206 (65.2) | 1.00 | 1.00 |
| Any exposure | 51 (38.4) | 110 (34.8) | 1.17 (0.77–1.77) | 1.06 (0.68–1.65) |
| Per 10 hr/week | 1.16 (1.00–1.35) | 1.12 (0.95–1.31) | ||
| 1 to < 5 hr/week | 17 (12.8) | 47 (14.9) | 0.91 (0.49–1.67) | 0.90 (0.47–1.72) |
| 5–60 hr/week | 34 (25.6) | 63 (19.9) | 1.36 (0.83–2.21) | 1.17 (0.69–1.95) |
| Any of the three office exposures | ||||
| No exposure (reference) | 38 (28.6) | 145 (45.9) | 1.00 | 1.00 |
| Any of the three exposures | 95 (71.4) | 171 (54.1) | 1.83 (1.04–3.22) | 1.90 (1.05–3.44) |
Logistic regression analysis: adjusted for age, sex, education (as a measure of socioeconomic status), smoking status, exposure to ETS (at home and/or work), exposure to molds (at home and/or work).
Any exposure to paper dust, CCP, and/or FPP.
| 1. Occurrence of at least one asthmatic symptom: prolonged cough, wheezing, attacks of or exercise-induced dyspnea, or nocturnal cough or wheezing |
| 2. Demonstration of reversibility in airways obstruction in lung function tests: |
| Significant improvement in response to short-acting bronchodilating medication in a bronchodilator test. The criteria for significant changes were: |
| FEV1 ≥ 15% |
| FVC ≥ 15% |
| PEF ≥ 23% |
| ≥ 20% daily variation |
| Significant improvement in spirometric lung function (for % criteria see above) and/or ≥ 20% improvement in the average PEF level in response to a 2-week oral steroid treatment |
FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; PEF, peak expiratory flow.
Calculated according to the standard practice of the Tampere University Hospital (National Asthma Program in Finland 1994): maximum daily variation = (highest PEF value during the day – lowest PEF value during the day)/highest PEF value during the day; bronchodilator response = (highest PEF value after bronchodilating medication – highest PEF value before medication)/highest PEF value before medication.